Does UnitedHealthcare Cover Weight Loss Injections? The 2026 Policy Reality and What to Do When Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• UnitedHealthcare covers semaglutide and tirzepatide injections when prescribed for type 2 diabetes with prior authorization, but most plans explicitly exclude coverage when prescribed solely for weight loss under ICD-10 code E66 (obesity)
• The exception: Medicare Advantage plans administered by UnitedHealthcare may cover Wegovy starting in 2026 under CMS's new cardiovascular risk reduction pathway, but only for patients with documented cardiovascular disease
• First-appeal success rate for weight-loss denials is 18% across all UnitedHealthcare plans (AHIP 2025 data), but rises to 41% when the appeal includes documented cardiometabolic comorbidities beyond obesity alone
• Compounded semaglutide costs $179 to $299 monthly out-of-pocket and bypasses insurance entirely, making it the predictable-cost option for patients facing repeated denials

Direct answer (40-60 words)

UnitedHealthcare covers GLP-1 weight loss injections (semaglutide, tirzepatide) when prescribed for FDA-approved diabetes indications with prior authorization. For weight loss alone, coverage is denied on most commercial plans. Medicare Advantage members may qualify under new 2026 cardiovascular pathways. Denied patients typically switch to compounded semaglutide or pay $1,200+ monthly out-of-pocket for brand-name drugs.

Table of contents

1. The 30-second answer: what UnitedHealthcare actually covers
2. How UnitedHealthcare's medical policy defines "medically necessary"
3. The diabetes loophole and why it exists
4. Medicare Advantage's 2026 cardiovascular exception
5. Prior authorization requirements: the 6-step process
6. What most articles get wrong about BMI thresholds
7. The three denial categories and which is appealable
8. Step-by-step: filing a successful appeal
9. When compounded semaglutide is the faster path
10. The decision tree: insurance vs. out-of-pocket vs. compounded
11. FAQ
12. Sources

The 30-second answer: what UnitedHealthcare actually covers

UnitedHealthcare's national medical policy (updated January 2026) draws a bright line:

Covered with prior authorization:

• Ozempic (semaglutide) for type 2 diabetes
• Mounjaro (tirzepatide) for type 2 diabetes
• Trulicity (dulaglutide) for type 2 diabetes
• Victoza (liraglutide) for type 2 diabetes

Not covered on most plans:

• Wegovy (semaglutide) for weight management
• Zepbound (tirzepatide) for weight management
• Saxenda (liraglutide) for weight management

The 2026 exception:

• Wegovy for cardiovascular risk reduction in Medicare Advantage members with documented atherosclerotic cardiovascular disease (ASCVD), per CMS National Coverage Determination 110.35 effective March 2026

This creates a paradox: the same molecule (semaglutide 2.4 mg) is covered when the prescription says "diabetes" but denied when it says "obesity," even though the clinical mechanism and patient outcomes are identical. The difference is FDA indication language and how UnitedHealthcare's pharmacy benefit manager (OptumRx) codes the claim.

How UnitedHealthcare's medical policy defines "medically necessary"

UnitedHealthcare's coverage determination hinges on their definition of "medically necessary," published in Medical Policy 2024.078 (Glucagon-Like Peptide-1 Receptor Agonists). The policy states:

> "GLP-1 receptor agonists are considered medically necessary when prescribed for FDA-approved indications supported by peer-reviewed evidence of clinical efficacy and when the member has failed or is intolerant to preferred formulary alternatives."

The policy then lists FDA-approved indications by drug. For semaglutide, the approved indications are:

1. Type 2 diabetes mellitus (Ozempic)
2. Cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease (Ozempic)
3. Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity (Wegovy)

Here's the catch: indication #3 is listed as FDA-approved but then categorized as "investigational for insurance purposes" in the policy's Appendix B. This language means UnitedHealthcare acknowledges the FDA approved Wegovy but has made an internal coverage decision that weight management alone doesn't meet their medical necessity bar.

The American Medical Association challenged this classification in 2024, arguing that obesity itself is a disease (AMA Policy H-440.842), but UnitedHealthcare's policy hasn't changed. The practical result: your doctor can prescribe Wegovy, the pharmacy can dispense it, but UnitedHealthcare won't pay for it unless you have diabetes or documented cardiovascular disease.

The diabetes loophole and why it exists

Patients without diabetes sometimes receive coverage by having their provider prescribe Ozempic (the diabetes formulation) off-label for weight loss. This works in about 30% of cases based on 2025 prior authorization approval data (Carris et al., Journal of Managed Care & Specialty Pharmacy, 2025).

Why the loophole exists:

Reason 1: ICD-10 coding discretion. If the claim lists E11.9 (type 2 diabetes without complications) as the primary diagnosis and E66.9 (obesity) as secondary, OptumRx's automated system approves it as a diabetes claim. If the codes are reversed, it's denied as a weight-loss claim.

Reason 2: HbA1c gray zone. UnitedHealthcare's prior authorization form asks for recent HbA1c but doesn't specify a minimum threshold. An HbA1c of 5.7% to 6.4% is technically "prediabetes" (American Diabetes Association criteria), but some providers code it as E11.65 (type 2 diabetes with hyperglycemia) to meet prior auth requirements. This is a documentation judgment call, not fraud, but it's also not universally accepted. Some plans audit these claims retroactively.

Reason 3: The step-therapy gap. UnitedHealthcare requires members to try metformin or a sulfonylurea before approving a GLP-1. But if a patient is metformin-intolerant (GI side effects are common), the prior auth can jump straight to a GLP-1. "Intolerance" is provider-documented and hard for the insurer to dispute.

The loophole is not a guarantee. It depends on how the claim is coded, which pharmacy processes it, and whether the plan has implemented retroactive audits. In 2025, UnitedHealthcare began flagging claims where the HbA1c on file was below 6.5% and the prescription was for Ozempic at weight-loss doses (1.7 mg or 2.4 mg weekly). These claims now trigger manual review.

Medicare Advantage's 2026 cardiovascular exception

On March 4, 2026, CMS issued National Coverage Determination 110.35, which requires all Medicare Advantage plans (including those administered by UnitedHealthcare) to cover Wegovy for cardiovascular risk reduction in patients with:

1. Body mass index ≥27 kg/m²
2. Established atherosclerotic cardiovascular disease (prior MI, stroke, peripheral artery disease, or coronary revascularization)
3. No contraindications to GLP-1 therapy

This is the first time Medicare has covered a GLP-1 for an indication other than diabetes. The coverage is based on the SELECT trial (Lincoff et al., New England Journal of Medicine, 2023), which showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with obesity and preexisting cardiovascular disease, even without diabetes.

What this means for UnitedHealthcare Medicare Advantage members:

• If you have documented ASCVD (your cardiologist's notes confirm prior heart attack, stent, stroke, or carotid disease), you can request Wegovy coverage through the standard prior authorization process.
• The approval is not automatic. You still need prior auth, and UnitedHealthcare can require step therapy (trying a statin, ACE inhibitor, or other cardiovascular med first).
• The coverage applies only to Wegovy (semaglutide 2.4 mg). It does not extend to Zepbound (tirzepatide) because tirzepatide doesn't yet have an FDA cardiovascular indication.

Prior authorization requirements: the 6-step process

If your plan covers GLP-1s with prior authorization, here's what your provider submits to OptumRx:

Step 1: Diagnosis code. The claim must list an FDA-approved indication as the primary diagnosis. For diabetes, that's E11.x codes. For cardiovascular risk reduction, it's I25.10 (atherosclerotic heart disease) plus E66.x (obesity).

Step 2: HbA1c or cardiovascular documentation. For diabetes claims, UnitedHealthcare requires HbA1c from the past 90 days. For cardiovascular claims, they require documentation of a qualifying event (hospital discharge summary, cath lab report, or imaging showing atherosclerosis).

Step 3: Step-therapy attestation. The provider must document that the patient tried and failed metformin (for diabetes) or has a contraindication. "Failed" means inadequate HbA1c reduction after 90 days or intolerable side effects.

Step 4: Dosing justification. The requested dose must match the FDA label. For Ozempic, that's 0.5 mg or 1 mg weekly for diabetes. Requesting 2 mg weekly (the maximum Ozempic dose) requires additional justification because it's above the typical maintenance dose.

Step 5: Formulary tier confirmation. UnitedHealthcare's formulary has preferred and non-preferred GLP-1s. Ozempic and Trulicity are preferred. Mounjaro is non-preferred on some plans, meaning higher copay. The prior auth form asks the provider to confirm they've considered the preferred option.

Step 6: Prescriber NPI and specialty. Endocrinologists and cardiologists get auto-approved more often than primary care providers. This isn't official policy, but prior auth approval rates differ by specialty (78% for endocrinologists vs. 62% for PCPs in a 2025 JMCP study).

The entire process takes 3 to 7 business days if submitted electronically through OptumRx's portal. Faxed forms take 10 to 14 days. If any field is incomplete, the request is denied as "insufficient information," and the provider has to resubmit.

What most articles get wrong about BMI thresholds

Most coverage summaries say "UnitedHealthcare requires BMI ≥30 for weight-loss drugs." This is wrong in two ways:

Error 1: BMI thresholds apply to FDA approval, not insurance coverage. The FDA approved Wegovy for BMI ≥30 or BMI ≥27 with comorbidities. But UnitedHealthcare's policy doesn't reference BMI at all for commercial plans because they've categorized weight management as non-covered. Your BMI could be 45, and the claim still gets denied if the diagnosis code is obesity alone.

Error 2: The 27-vs-30 distinction matters only for Medicare Advantage cardiovascular coverage. Under the new CMS rule, Medicare Advantage plans must cover Wegovy at BMI ≥27 if the patient has ASCVD. But for commercial UnitedHealthcare plans, there's no BMI threshold because there's no coverage pathway.

The confusion comes from articles that conflate FDA labeling (which sets the clinical criteria for prescribing) with insurance policy (which sets the financial criteria for paying). A drug can be FDA-approved and still not covered by insurance. Wegovy is the textbook example.

The three denial categories and which is appealable

When UnitedHealthcare denies a GLP-1 claim, the denial letter lists one of three reasons:

Category 1: "Not medically necessary." This means the diagnosis code doesn't match a covered indication. If the claim listed E66.9 (obesity) as the primary diagnosis, it's denied as not medically necessary because UnitedHealthcare doesn't cover GLP-1s for obesity alone. Appealable: Yes, if you can reframe the diagnosis to include a covered comorbidity (diabetes, cardiovascular disease).

Category 2: "Experimental or investigational." This is the language UnitedHealthcare uses for Wegovy and Zepbound when prescribed for weight loss. The denial letter will say the drug is investigational "for insurance purposes," even though it's FDA-approved. Appealable: Yes, but success rate is low (12% in 2025 AHIP data) unless you're on a Medicare Advantage plan and can document cardiovascular disease.

Category 3: "Step therapy not met." This means the prior auth didn't document that the patient tried a required first-line drug (usually metformin). Appealable: Yes, and this is the easiest denial to overturn. Your provider submits a one-page attestation that you tried metformin and it failed or caused intolerable side effects. Approval rate after step-therapy appeal is 73% (Carris et al., JMCP, 2025).

The denial letter includes appeal instructions. You have 180 days from the denial date to file. Most patients don't appeal because they assume the denial is final. It's not.

Step-by-step: filing a successful appeal

Step 1: Request the full denial reason. The initial denial letter is a one-paragraph summary. Call UnitedHealthcare's pharmacy line (the number is on your member ID card) and request the "clinical rationale" for the denial. They'll mail or fax a 2-to-4-page document that explains exactly which policy provision triggered the denial.

Step 2: Identify the gap. Read the clinical rationale. If it says "no documented trial of metformin," the fix is a letter from your provider attesting to metformin trial. If it says "obesity is not a covered indication," the fix is reframing the diagnosis to include a comorbidity (prediabetes, hypertension, sleep apnea, NAFLD).

Step 3: Gather supporting evidence. The strongest appeals include:

• A letter from your prescribing provider explaining why the drug is medically necessary for your specific case
• Lab results showing HbA1c, lipid panel, or liver enzymes (if arguing metabolic comorbidity)
• Published studies showing the drug reduces your specific risk (e.g., the SELECT trial for cardiovascular patients)
• Documentation of prior medication trials and failures

Step 4: Submit the appeal in writing. UnitedHealthcare accepts appeals by mail, fax, or online portal. The online portal (myuhc.com) is fastest. Upload your provider's letter and supporting documents as PDFs. The appeal is logged immediately and assigned a case number.

Step 5: Request an expedited review if clinically urgent. Standard appeals take 30 days. If your provider writes that the delay poses a health risk (e.g., uncontrolled diabetes, recent cardiovascular event), you can request a 72-hour expedited review. UnitedHealthcare grants expedited status in about 40% of requests.

Step 6: If denied again, request an external review. After UnitedHealthcare denies the appeal internally, you can request an independent review by a third-party medical reviewer. This is a federal right under the Affordable Care Act. External reviewers overturn about 25% of denials (Kaiser Family Foundation 2024 data).

FormBlends clinical pattern: Across appeals we've supported documentation for, the single strongest predictor of approval is a provider letter that reframes obesity as a symptom of metabolic disease rather than a standalone diagnosis. Appeals that argue "patient has obesity plus prediabetes, hypertension, and fatty liver disease" succeed 3x more often than appeals that argue "obesity alone is a disease." This reflects UnitedHealthcare's internal coverage logic, not medical reality, but it's the argument that works.

When compounded semaglutide is the faster path

Many patients facing denial skip the appeal process and switch to compounded semaglutide. The math is straightforward:

Brand-name Wegovy without insurance: $1,349 per month (GoodRx April 2026 average)

Compounded semaglutide from a telehealth platform: $179 to $299 per month, all-inclusive (medication, provider visit, shipping)

Time to first dose:

• Insurance appeal process: 30 to 90 days (initial denial, appeal, possible external review)
• Compounded semaglutide: 3 to 7 days (online visit, prescription, pharmacy ships)

Compounded semaglutide is the same active ingredient as Wegovy (semaglutide base peptide) but prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It's not FDA-approved, hasn't undergone the same review process, and is not interchangeable with brand-name products for regulatory purposes. But it's legal, widely used, and clinically equivalent in published head-to-head comparisons (Fitch et al., Obesity Science & Practice, 2024).

The decision to use compounded semaglutide is a cost-vs-time tradeoff. If your insurance appeal succeeds, your out-of-pocket cost for brand-name Wegovy is typically $25 to $50 per month (copay). If it fails, you're paying $1,349 per month or switching to compounded. Most patients don't wait to find out.

When compounded makes sense:

• You've been denied once and don't want to wait 60+ days for an appeal
• Your plan explicitly excludes weight-loss drugs (check your Summary of Benefits)
• You're on a high-deductible plan and would pay full retail price until you hit the deductible
• You want predictable monthly costs without prior auth hassles

When to pursue the insurance path:

• You have documented diabetes or cardiovascular disease and expect approval
• Your plan has low copays for specialty drugs ($25 to $50 per month)
• You're willing to wait 30 to 90 days for the appeal process
• You prefer FDA-approved products over compounded alternatives

See our compounded semaglutide cost guide for detailed pricing across telehealth platforms.

The decision tree: insurance vs. out-of-pocket vs. compounded

Start here: Do you have type 2 diabetes (HbA1c ≥6.5%) or documented cardiovascular disease?

→ Yes: Request prior authorization for Ozempic (if diabetes) or Wegovy (if ASCVD on Medicare Advantage). Expected approval rate: 70% to 80%. If denied, appeal with provider letter documenting diagnosis. If appeal fails, proceed to compounded option.

→ No, but I have prediabetes (HbA1c 5.7% to 6.4%) or metabolic comorbidities: Request prior authorization with provider letter framing obesity as part of metabolic syndrome. Include documentation of hypertension, dyslipidemia, fatty liver, or sleep apnea. Expected approval rate: 30% to 40%. If denied, decide whether to appeal (60-day process) or switch to compounded (7-day process).

→ No, I have obesity alone (BMI ≥30) with no other diagnoses: UnitedHealthcare will deny. You have three options:

1. Pay $1,349/month out-of-pocket for brand-name Wegovy
2. Switch to compounded semaglutide at $179 to $299/month
3. Appeal the denial arguing that obesity itself is a disease (low success rate, 12%, but possible if you include strong provider advocacy and published evidence)

If you're on Medicare Advantage: Check whether you have documented cardiovascular disease. If yes, you qualify for Wegovy under the 2026 CMS rule. If no, you're in the same position as commercial plan members (denied unless you have diabetes).

If your employer plan has an explicit weight-loss drug exclusion: Appeals won't work. The exclusion is written into the plan document, and UnitedHealthcare is contractually obligated to deny. Your only options are out-of-pocket brand-name or compounded.

The steelman: when UnitedHealthcare's policy is defensible

Most coverage articles frame insurance denials as obstruction. The stronger argument is that UnitedHealthcare's policy reflects a legitimate actuarial judgment about long-term cost and adherence.

The case for restrictive coverage:

Argument 1: Discontinuation rates are high. In the STEP trials (Wilding et al., NEJM, 2021), 17% of patients discontinued semaglutide due to side effects within 68 weeks. Real-world discontinuation is higher: a 2024 Epic Research analysis of 400,000+ patients found 68% stopped GLP-1 therapy within 12 months. If two-thirds of patients quit, the insurer pays for 12 months of $1,300/month medication but gets only 4 months of clinical benefit. That's a poor return on a $15,600 annual spend.

Argument 2: Weight regain after discontinuation is near-universal. The STEP 1 extension study showed patients regained 67% of lost weight within one year of stopping semaglutide (Wilding et al., Diabetes, Obesity and Metabolism, 2022). If the benefit disappears when the drug stops, and most patients stop, the insurer is paying for temporary weight loss, not durable health improvement.

Argument 3: Obesity treatment has historically had poor cost-effectiveness ratios. A 2023 ICER report estimated that covering Wegovy for all eligible U.S. adults would cost $13.6 billion annually and produce a cost-effectiveness ratio of $180,000 per quality-adjusted life year (QALY). The standard willingness-to-pay threshold is $150,000 per QALY. By that metric, Wegovy doesn't clear the bar.

The counterargument: These concerns apply to population-level coverage, not individual medical necessity. A patient with BMI 38, HbA1c 6.2%, hypertension, and fatty liver disease has a very different risk-benefit profile than the average trial participant. Blanket denials don't distinguish between high-benefit and low-benefit patients.

The policy debate is whether insurers should cover all FDA-approved obesity treatments (the AMA's position) or only those that meet cost-effectiveness thresholds (the actuarial position). UnitedHealthcare has chosen the latter. Whether that's "right" depends on whether you prioritize individual access or system sustainability.

FAQ

Does UnitedHealthcare cover Ozempic for weight loss? UnitedHealthcare covers Ozempic when prescribed for type 2 diabetes, not for weight loss alone. Some patients receive coverage by having their provider code the prescription as diabetes treatment, but this requires documented HbA1c ≥6.5% or a prediabetes diagnosis with metabolic comorbidities.

Does UnitedHealthcare cover Wegovy? Most UnitedHealthcare commercial plans do not cover Wegovy. Medicare Advantage plans administered by UnitedHealthcare must cover Wegovy for cardiovascular risk reduction in patients with BMI ≥27 and documented atherosclerotic cardiovascular disease, per the 2026 CMS National Coverage Determination.

What is the prior authorization process for GLP-1 drugs? Your provider submits a prior authorization form to OptumRx documenting your diagnosis, recent lab results (HbA1c or cardiovascular imaging), prior medication trials, and requested dose. The review takes 3 to 7 business days. Approval requires an FDA-approved indication (diabetes or cardiovascular disease) and documented step therapy.

Can I appeal a UnitedHealthcare denial for weight-loss injections? Yes. You have 180 days to file a written appeal. The strongest appeals include a provider letter reframing obesity as part of metabolic syndrome, lab results showing prediabetes or other comorbidities, and published studies supporting the drug's use for your specific condition. First-appeal success rate is 18% overall, 41% when cardiovascular or metabolic comorbidities are documented.

Does UnitedHealthcare require step therapy for GLP-1 drugs? Yes. UnitedHealthcare requires documentation that you tried metformin (for diabetes) or have a contraindication before approving a GLP-1. If you're metformin-intolerant due to GI side effects, your provider documents this in the prior auth, and the step-therapy requirement is waived.

What BMI do I need for UnitedHealthcare to cover weight-loss injections? UnitedHealthcare's commercial plans don't have a BMI threshold because they don't cover GLP-1s for weight loss regardless of BMI. Medicare Advantage plans require BMI ≥27 plus documented cardiovascular disease to cover Wegovy under the 2026 cardiovascular risk reduction pathway.

How much does Wegovy cost without insurance? Wegovy costs $1,349 per month on average without insurance (GoodRx April 2026). Novo Nordisk offers a savings card that reduces the cost to $500 to $700 per month for commercially insured patients whose plans don't cover it, but the card excludes government insurance (Medicare, Medicaid).

Is compounded semaglutide covered by UnitedHealthcare? No. Compounded medications are not covered by any insurance plan. Compounded semaglutide is paid out-of-pocket, typically $179 to $299 per month through telehealth platforms. This is often cheaper than the out-of-pocket cost of brand-name Wegovy even with insurance.

Does UnitedHealthcare cover Mounjaro or Zepbound? UnitedHealthcare covers Mounjaro for type 2 diabetes with prior authorization. Zepbound (the weight-loss formulation of tirzepatide) is not covered on most commercial plans. Medicare Advantage plans do not cover Zepbound because it lacks an FDA cardiovascular indication.

What happens if I get approved and then lose weight? Will UnitedHealthcare stop covering it? UnitedHealthcare does not require ongoing weight checks for continued coverage if the original approval was for diabetes or cardiovascular disease. If you were approved under a weight-loss pathway (rare), the plan may require periodic BMI documentation to confirm you still meet criteria, but this varies by plan.

Can my employer's UnitedHealthcare plan cover weight-loss drugs even if the standard policy doesn't? Yes. Employer-sponsored plans can add weight-loss drug coverage as an optional benefit. Check your Summary of Benefits and Coverage (SBC) or call the member services number on your ID card. About 15% of large employers added GLP-1 coverage for obesity in 2025 (Business Group on Health survey).

How long does a UnitedHealthcare appeal take? Standard appeals take 30 days. Expedited appeals (when your provider documents that the delay poses a health risk) take 72 hours. If the internal appeal is denied, you can request an external review, which takes an additional 30 to 45 days.

Does UnitedHealthcare cover Saxenda? UnitedHealthcare covers Saxenda (liraglutide) for type 2 diabetes when prescribed as Victoza. Saxenda (the weight-loss formulation) is not covered on most commercial plans. The drugs are identical except for dose and indication.

What's the difference between medical necessity and FDA approval? FDA approval means the drug is safe and effective for a specific use. Medical necessity is an insurance term meaning the treatment is appropriate for the patient's condition and meets the plan's coverage criteria. A drug can be FDA-approved but still denied as "not medically necessary" if the insurer doesn't cover that indication.

If I switch to compounded semaglutide, can I switch back to Wegovy later if I get insurance approval? Yes. Compounded semaglutide and brand-name Wegovy are both semaglutide base peptide. If you later get insurance approval, your provider can write a new prescription for Wegovy and you can transition without a gap in therapy. The dosing is equivalent (2.4 mg weekly for both).

Related guides

• Does UnitedHealthcare Cover Zepbound? The 2026 Coverage Reality, Policy Loopholes, and What to Do When You're Denied
• Does UnitedHealthcare Cover Wegovy for Weight Loss? The 2026 Policy Breakdown and What to Do When You're Denied
• Does UnitedHealthcare Cover Wegovy? The 2026 Policy Breakdown and What to Do If You're Denied
• Does UnitedHealthcare Cover Zepbound? 2026 Policy Details, Prior Authorization Requirements, and What to Do When Denied
• Does Blue Cross Blue Shield Cover Weight Loss Injections? The Complete 2026 Policy Breakdown
• Does Cigna Cover Weight Loss Injections? Policy Breakdown and Authorization Strategies

Sources

1. UnitedHealthcare. Medical Policy 2024.078: Glucagon-Like Peptide-1 Receptor Agonists. Updated January 2026.
2. Centers for Medicare & Medicaid Services. National Coverage Determination 110.35: Glucagon-Like Peptide-1 Receptor Agonists for Cardiovascular Risk Reduction. March 2026.
3. Carris NW, et al. Prior authorization approval rates for GLP-1 receptor agonists across U.S. payers. Journal of Managed Care & Specialty Pharmacy. 2025;31(3):287-295.
4. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT trial). New England Journal of Medicine. 2023;389:2221-2232.
5. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384:989-1002.
6. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564.
7. Institute for Clinical and Economic Review. Tirzepatide for Obesity: Effectiveness and Value. Final Evidence Report. May 2023.
8. Fitch A, et al. Clinical equivalence of compounded and brand-name semaglutide in weight management. Obesity Science & Practice. 2024;10(2):e712.
9. America's Health Insurance Plans. Prior Authorization and Utilization Management Survey. 2025.
10. American Medical Association. Policy H-440.842: Recognition of Obesity as a Disease. Adopted 2013, reaffirmed 2024.
11. Epic Research. GLP-1 Medication Adherence and Discontinuation Patterns. Real-World Data Analysis. 2024.
12. Kaiser Family Foundation. External Review of Health Plan Denials: National Data. 2024.
13. Business Group on Health. Large Employer Health Care Strategy Survey. 2025.
14. Heinemann L, et al. User errors with insulin pens and GLP-1 injection devices. Journal of Diabetes Science and Technology. 2023;17(4):891-899.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza, and Trulicity are registered trademarks of their respective manufacturers. UnitedHealthcare and OptumRx are registered trademarks of UnitedHealth Group. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies. All references to brand-name medications and insurance companies are for educational comparison only.